In addition, we intended to examine potential influence of PCSK9 inhibitor therapy on glycemic control assessed by HbA1c and evaluated whether there were differences in LDL-C reduction efficacy in those with and without T2D. Here, PCSK9 is linked to type 2 diabetes mellitus.